Coverart for item
The Resource Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos

Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos

Label
Surgery in rheumatic and musculoskeletal disease
Title
Surgery in rheumatic and musculoskeletal disease
Statement of responsibility
editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos
Contributor
Editor
Subject
Language
eng
Summary
"Surgery in Systemic Autoimmune Disease, Volume 15, describes the state-of-the-art of the use of surgery in treating the most common systemic autoimmune diseases (SADS). The volume consists of an introductory chapter concerning the impact of surgery on SADs, follow by eight chapters describing the use of surgery in the treatment of specific diseases in various areas (cardiology, gastroenterology, orthopedics, neurology. etc.) and the possible difficulties and complications. The final five chapters deal with the possible complications arising during the course of biological and non-biological treatment, also providing recommendation concerning their management. International in scope, the list of more than 20 contributors from Europa and America reads like a who's who of clinical researchers in the field. Written by leading international clinical/surgical and scientific experts on surgical problems in SADsProvides a practical guide to the safer use of surgery in patients with autoimmune diseasesIncludes a number of problems and recommendations that cannot be found in other booksDesigned as a 'guide to clinical practice' for surgical interventions required by patients with SADsGives a comprehensive review of the available surgical options"--
Member of
Assigning source
Provided by publisher
Cataloging source
N$T
Dewey number
617.4
Index
index present
LC call number
RD605.2
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
http://library.link/vocab/relatedWorkOrContributorName
  • Atzeni, Fabiola
  • Masala, Ignazio Francesco
  • Aletaha, Daniel
Series statement
Handbook of systemic autoimmune diseases
Series volume
15
http://library.link/vocab/subjectName
  • Autoimmune diseases
  • Rheumatism
  • Musculoskeletal system
Label
Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos
Instantiates
Publication
Copyright
Antecedent source
unknown
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • Front Cover; Surgery in Rheumatic and Musculoskeletal Disease; Handbook of Systemic Autoimmune Diseases; Surgery in Rheumatic and Musculoskeletal Disease; Copyright; Dedication; Contents; List of Contributors; Preface; 1 -- The Spectrum of Rheumatic Diseases; 1. INTRODUCTION; 2. SYSTEMIC AUTOIMMUNE DISEASES; 2.1 Systemic Lupus Erythematosus; 2.2 Rheumatoid Arthritis; 2.3 Systemic Sclerosis; 2.4 Idiopathic Inflammatory Myopathies; 2.5 Antiphospholipid Syndrome; 3. AUTOINFLAMMATORY DISEASES; 4. METABOLIC DISEASES; 4.1 Osteoporosis; 4.2 Crystal Deposition Disease
  • 4.2.1 Calcium Pyrophosphate Disease (CPPD)4.3 Gout; 5. DEGENERATIVE DISEASES; 5.1 Osteoarthritis; 6. CONCLUSIONS; KEYPOINTS; REFERENCES; 2 -- Comorbidities in Patients With Rheumatic Disease; 1. INTRODUCTION; 1.1 The Concepts of Comorbidity and Multimorbidity; 1.2 Prevalence of Multimorbidity in Rheumatic Conditions; 2. ASSESSMENT OF COMORBID CONDITIONS; 3. IMPACT OF COMORBIDITIES ON IMPORTANT OUTCOMES; 3.1 Mortality; 3.2 Health Economic Implications; 3.3 Disease-Related Outcomes; 3.4 Outcomes Related to Surgery; 4. DISTINCT COMORBID CONDITIONS; 4.1 Cardiovascular Disease
  • 4.2 Pulmonary Disease4.3 Malignancies; 4.4 Gastrointestinal Disease; 4.5 Infections; 4.6 Osteoporosis; 4.7 Depression; 5. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; REFERENCES; 3 -- Drugs Used in Rheumatic Disease; 1. INTRODUCTION; 2. NONSTEROIDAL ANTIINFLAMMATORY DRUGS; 3. GLUCOCORTICOIDS; 4. IMMUNOSUPPRESSANTS/IMMUNOMODULATORS AND DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 4.1 Nonbiological Agents; 4.1.1 Methotrexate; 4.1.2 Leflunomide; 4.1.3 Sulfasalazine; 4.1.4 Antimalarials; 4.1.5 Cyclophosphamide; 4.1.6 Azatihioprine; 4.1.7 Mycophenolate Mofetil
  • 4.1.8 Cyclosporine and Tacrolimus4.1.9 Apremilast; 4.1.10 Tofacitinib; 4.2 Biologicals; 4.2.1 Tumor Necrosis Factor-Alpha Inhibitors; 4.2.2 Tocilizumab; 4.2.3 Anakinra, Canakinumab, and Rilonacept; 4.2.4 Rituximab; 4.2.5 Abatacept; 4.2.6 Secukinumab; 4.2.7 Ustekinumab; 4.2.8 Belimumab; 5. COLCHICINE; 6. URATE-LOWERING AGENTS; 7. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; DEDICATION; REFERENCES; 4 -- Essential and Optional Drugs for Rheumatic Diseases; 1. RHEUMATOID ARTHRITIS AND SPONDYLARTHRITIDES; 2. GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA; 3. VASCULITIDES
  • 4. CONNECTIVE TISSUE DISEASES5. BASIC LABORATORY ASSESSMENT; 6. GLUCOCORTICOIDS; 7. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; 8. DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 9. ANTIMALARIALS; 10. CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 10.1 Methotrexate; 10.2 Sulfasalazine; 10.3 Leflunomide; 11. BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 11.1 Tumor Necrosis Factor Blockers (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab); 11.2 Interleukin-1 (Receptor) Blockade (Anakinra, Canakinumab); 11.3 Interleukin-6 (Receptor) Blockade (Sarilumab, Tocilizumab)
Control code
SCIDI1029872305
Dimensions
unknown
Extent
1 online resource.
File format
unknown
Form of item
online
Isbn
9780444638885
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Note
Online access with subscription: Elsevier (Sciencedirect Freedom Collection)
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
  • on1029872305
  • (OCoLC)1029872305
Label
Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos
Publication
Copyright
Antecedent source
unknown
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • Front Cover; Surgery in Rheumatic and Musculoskeletal Disease; Handbook of Systemic Autoimmune Diseases; Surgery in Rheumatic and Musculoskeletal Disease; Copyright; Dedication; Contents; List of Contributors; Preface; 1 -- The Spectrum of Rheumatic Diseases; 1. INTRODUCTION; 2. SYSTEMIC AUTOIMMUNE DISEASES; 2.1 Systemic Lupus Erythematosus; 2.2 Rheumatoid Arthritis; 2.3 Systemic Sclerosis; 2.4 Idiopathic Inflammatory Myopathies; 2.5 Antiphospholipid Syndrome; 3. AUTOINFLAMMATORY DISEASES; 4. METABOLIC DISEASES; 4.1 Osteoporosis; 4.2 Crystal Deposition Disease
  • 4.2.1 Calcium Pyrophosphate Disease (CPPD)4.3 Gout; 5. DEGENERATIVE DISEASES; 5.1 Osteoarthritis; 6. CONCLUSIONS; KEYPOINTS; REFERENCES; 2 -- Comorbidities in Patients With Rheumatic Disease; 1. INTRODUCTION; 1.1 The Concepts of Comorbidity and Multimorbidity; 1.2 Prevalence of Multimorbidity in Rheumatic Conditions; 2. ASSESSMENT OF COMORBID CONDITIONS; 3. IMPACT OF COMORBIDITIES ON IMPORTANT OUTCOMES; 3.1 Mortality; 3.2 Health Economic Implications; 3.3 Disease-Related Outcomes; 3.4 Outcomes Related to Surgery; 4. DISTINCT COMORBID CONDITIONS; 4.1 Cardiovascular Disease
  • 4.2 Pulmonary Disease4.3 Malignancies; 4.4 Gastrointestinal Disease; 4.5 Infections; 4.6 Osteoporosis; 4.7 Depression; 5. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; REFERENCES; 3 -- Drugs Used in Rheumatic Disease; 1. INTRODUCTION; 2. NONSTEROIDAL ANTIINFLAMMATORY DRUGS; 3. GLUCOCORTICOIDS; 4. IMMUNOSUPPRESSANTS/IMMUNOMODULATORS AND DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 4.1 Nonbiological Agents; 4.1.1 Methotrexate; 4.1.2 Leflunomide; 4.1.3 Sulfasalazine; 4.1.4 Antimalarials; 4.1.5 Cyclophosphamide; 4.1.6 Azatihioprine; 4.1.7 Mycophenolate Mofetil
  • 4.1.8 Cyclosporine and Tacrolimus4.1.9 Apremilast; 4.1.10 Tofacitinib; 4.2 Biologicals; 4.2.1 Tumor Necrosis Factor-Alpha Inhibitors; 4.2.2 Tocilizumab; 4.2.3 Anakinra, Canakinumab, and Rilonacept; 4.2.4 Rituximab; 4.2.5 Abatacept; 4.2.6 Secukinumab; 4.2.7 Ustekinumab; 4.2.8 Belimumab; 5. COLCHICINE; 6. URATE-LOWERING AGENTS; 7. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; DEDICATION; REFERENCES; 4 -- Essential and Optional Drugs for Rheumatic Diseases; 1. RHEUMATOID ARTHRITIS AND SPONDYLARTHRITIDES; 2. GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA; 3. VASCULITIDES
  • 4. CONNECTIVE TISSUE DISEASES5. BASIC LABORATORY ASSESSMENT; 6. GLUCOCORTICOIDS; 7. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; 8. DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 9. ANTIMALARIALS; 10. CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 10.1 Methotrexate; 10.2 Sulfasalazine; 10.3 Leflunomide; 11. BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 11.1 Tumor Necrosis Factor Blockers (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab); 11.2 Interleukin-1 (Receptor) Blockade (Anakinra, Canakinumab); 11.3 Interleukin-6 (Receptor) Blockade (Sarilumab, Tocilizumab)
Control code
SCIDI1029872305
Dimensions
unknown
Extent
1 online resource.
File format
unknown
Form of item
online
Isbn
9780444638885
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Note
Online access with subscription: Elsevier (Sciencedirect Freedom Collection)
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
  • on1029872305
  • (OCoLC)1029872305

Library Locations